HomeInsightsStock Comparison

Bharat Immunological Biological Corporation Ltd vs Natco Pharma Ltd Stock Comparison

Bharat Immunological Biological Corporation Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 20, 2025

Key Highlights

  • The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 24.17 as of 20 Jun 12:30.
  • The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bharat Immunological & Biological Corporation Ltd

  • The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
  • BIBCOL was incorporated in 1989.
  • The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
  • BIBCL installed a plant of 100 mln units.
  • Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Natco Pharma Ltd

  • Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited.
  • It became a deemed public company with effect from 1 July 1992.
  • The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993.
  • The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.

Bharat Immunological & Biological Corporation Ltd News Hub

News

Bharat Immunological & Biological Corporation Ltd leads losers in 'B' group

Relicab Cable Manufacturing Ltd, Precision Wires India Ltd, Brainbees Solutions Ltd and Fl...

Read more

08 Jan 2025 14:45

News

Bharat Immunological & Biological Corporation Ltd leads gainers in 'B' group

Bodhi Tree Multimedia Ltd, Mangal Credit & Fincorp Ltd, Innovana Thinklabs Ltd and Bartron...

Read more

06 Jan 2025 12:15

News

Bharat Immunological & Biolog.Corp. to hold board meeting

Bharat Immunological & Biolog.Corp. will hold a meeting of the Board of Directors of the C...

Read more

10 Aug 2024 17:28

News

Bharat Immunological & Biolog.Corp. announces board meeting date

Bharat Immunological & Biolog.Corp. will hold a meeting of the Board of Directors of the C...

Read more

01 Mar 2024 10:22

News

Bharat Immunological & Biolog.Corp. to convene AGM

Bharat Immunological & Biolog.Corp. announced that the 34th Annual General Meeting (AGM) o...

Read more

29 Nov 2023 10:47

News

Bharat Immunological & Biolog.Corp. to conduct AGM

Bharat Immunological & Biolog.Corp. announced that the 34th Annual General Meeting (AGM) o...

Read more

28 Nov 2023 18:37

Natco Pharma Ltd News Hub

News

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 ...

Read more

20 Jun 2025 09:54

News

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483. The...

Read more

14 Jun 2025 13:45

News

Natco Pharma's Mekaguda API unit completes USFDA inspection

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active P...

Read more

13 Jun 2025 16:27

News

Natco Pharma Ltd gains for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908...

Read more

11 Jun 2025 13:05

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

SWOT Analysis Of Bharat Immunological & Biological Corporation Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Bharat Immunological & Biological Corporation Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Natco Pharma Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 104 Cr while Market cap of Natco Pharma Ltd is 15,785 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd?

As of June 20, 2025, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹24.17. On the other hand, Natco Pharma Ltd stock price is INR ₹881.35.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions